AB Science

Company snapshot

AB Science was founded in 2001 by a team of researchers, clinicians and entrepreneurs who have dedicated their lives to discover key mechanisms in life science and develop new drugs targeting these mechanisms to dramatically change the life of patients in the most unmet medical needs. We are innovators and scientific entrepreneurs in the field of life science. Our group is specialized in targeted

• 6 active pipeline program(s) linked via ClinicalTrials.gov.
• 25 US patent(s) indexed to this assignee profile.
• 6 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for AB Science. Not investment advice.

• Peer + 0 momentum

  Teva Pharma

  TA overlap score 40

• Peer + 0 momentum

  Jazz Pharmaceuticals Ireland

  TA overlap score 40

Recent activity

Latest pipeline, patent, and corporate events for AB Science.

1. Jun 8, 2026 Clinical update

   AB23005 — Phase 3

2. Jun 8, 2026 Clinical update

   AB20009 — Phase 3

3. Jun 8, 2026 Clinical update

   AB20006 — Phase 2

4. Jun 8, 2026 Clinical update

   AB19001 — Phase 3

5. Jun 8, 2026 Clinical update

   AB18001 — Phase 2

View all clinical trial activity →

• What is AB Science?

  AB Science is a pharma organization headquartered in PARIS, FR. Primary therapeutic focus areas include Amyotrophic Lateral Sclerosis, Acute Myeloid Leukemia, Mastocytosis, Mast cell activation syndrome, Multiple Sclerosis. NovaPharmaNews links 6 clinical program(s), 0 drug profi

• Is AB Science publicly traded?

  AB Science appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does AB Science develop or market?

  We link 11 drug profile(s) where AB Science is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ab-science#company-drugs.

• What are the latest developments for AB Science?

  In the last 12 months our linked public records show 6 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does AB Science focus on?

  AB Science focuses on Amyotrophic Lateral Sclerosis, Acute Myeloid Leukemia, Mastocytosis based on our analysis of their pipeline programs and drug development activities.